Crohn's Is on the Rise Among Children

Study To Determine Which Kids Will Benefit From New Drugs

Kate Goldbaum (center left) weighed only 85 pounds as a 14-year-old; she put off taking ‘biologics.’
courtesy kate goldbaum
Kate Goldbaum (center left) weighed only 85 pounds as a 14-year-old; she put off taking ‘biologics.’

By Hannah Rubin

Published August 17, 2012, issue of August 17, 2012.
  • Print
  • Share Share
  • Single Page

Last February, on a warm day in North Carolina, Dr. David Wohl entered the playground and saw his eight-year-old son, Zac, sitting motionless in the sandbox. “He looked like a 90-year-old guy who had fallen and couldn’t get up,” said Wohl, an AIDS expert and associate professor of infectious diseases at the University of North Carolina, Chapel Hill.

A few days later, after Zac was gripped by multiple intensive stomachaches, he was rushed to the hospital. “He was having 15 to 20 bellyaches a day. His grandmother could tell something was wrong by just looking at him,” Wohl said.

Zac was diagnosed with Crohn’s disease, a lifelong inflammatory bowel disease (IBD) that affects about 1.4 million Americans, most often Caucasians — and, even more often, Ashkenazi Jews. Studies have shown that as many as 317 of every 100,000 North Americans have Crohn’s disease, but among the Ashkenazi Jewish population, it is two to four times more prevalent. And for unknown reasons, it’s on the rise, among children in particular.

“Children under 18 [are] the fastest-growing patient population,” said Dr. Ted Densen, medical director of Cincinnati’s Children’s Hospital Medical Center’s Inflammatory Bowel Disease Center. “One in five children that are diagnosed with IBD present it with severe disease.” Symptoms can range from mild stomach pain and constipation to more severe aches, fatigue, diarrhea, bleeding and infection.

Although the doctors could diagnose Zac, they were unable to cure him: Crohn’s currently has neither a clear-cut cause nor a treatment. “IBD is not a one-size-fits-all disease,” said Dr. Sandra Kim, assistant professor of pediatrics at UNC School of Medicine and chair of pediatric affairs at the Crohn’s and Colitis Foundation of America. “Just because a treatment works on one kid does not mean it will have the same effects on another. Kids with IBD also have unique characteristics that are different from adults.”

With no standard path of treatment, Zac’s family was left with lots of decisions, none of them easy. “There was a lot of handwringing, because the doctor doesn’t tell you explicitly what you should do,” Wohl said. “She lays out all of the options, but you have to make the decision yourself. One of the drugs recommended to us carries the possibility of fatal lymphoma; another has toxic effects on child development. It was heart-wrenching.”

When Zac’s gastroenterologist, Kim, asked the family in April if they wanted to enroll Zac in a nationwide pediatric Crohn’s research study, Wohl did not hesitate. The study, known as the Pediatric RISK Stratification Project (RISK) — overseen by the Crohn’s and Colitis Foundation in partnership with 29 medical centers — is not testing a treatment. Rather, it is assembling, through blood and stool samples, the largest ever database of information from children with IBD. Since 2008, it has enrolled more than 1,740 children, with the goal of creating individualized patient profiles to better predict who is at risk for the severest form of the disease and which drugs will work best with whom. “The hope is that we can develop a model that will allow us to predict how a child’s disease will progress, or how they will respond to certain medications,” said Kim, who oversees the RISK study at UNC.

For many years, the only treatments for IBD were anti-inflammatory medications, such as sulfasalazine and mesalamine, which try to reduce symptoms by targeting the inflammation. But they often didn’t work well on the patients most severely affected and came with a plethora of side effects, such as nausea, diarrhea and insomnia. While corticosteroids remain a popular choice for short-term remission, pediatricians are particularly hesitant to prescribe them to adolescent patients because they can lead to stunted growth.

Another class of drugs, immunosuppressives, works by tamping down the immune system, thus alleviating the body’s fight against itself. Only one such drug, Purinethol is still regularly used, with varying levels of efficacy.

Alternatively, patients and their doctors try to control flair ups through special diets.

The most aggressive treatments are called biologics — intravenous infusions that target the immune system through a new mechanism: by binding to and suppressing a protein produced by the immune system known as Tumor Necrosis Factor (TNF). The anti-TNF biologic disables TNF in the bloodstream before it can damage the intestines. The infusion is administered every six to eight weeks and is a lifelong commitment: If you miss a treatment, the body may build up a resistance to the drug, rendering it ineffective.


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • "If you want my advice: more Palestinians, more checkpoints, just more reality." What do you think?
  • Happy birthday Barbra Streisand! Our favorite Funny Girl turns 72 today.
  • Clueless parenting advice from the star of "Clueless."
  • Why won't the city give an answer?
  • BREAKING NEWS: Israel has officially suspended peace talks with the Palestinians.
  • Can you guess what the most boring job in the army is?
  • What the foolish rabbi of Chelm teaches us about Israel and the Palestinian unity deal:
  • Mazel tov to Idina Menzel on making Variety "Power of Women" cover! http://jd.fo/f3Mms
  • "How much should I expect him and/or ask him to participate? Is it enough to have one parent reciting the prayers and observing the holidays?" What do you think?
  • New York and Montreal have been at odds for far too long. Stop the bagel wars, sign our bagel peace treaty!
  • Really, can you blame them?
  • “How I Stopped Hating Women of the Wall and Started Talking to My Mother.” Will you see it?
  • Taglit-Birthright Israel is redefining who they consider "Jewish" after a 17% drop in registration from 2011-2013. Is the "propaganda tag" keeping young people away?
  • Happy birthday William Shakespeare! Turns out, the Bard knew quite a bit about Jews.
  • Would you get to know racists on a first-name basis if you thought it might help you prevent them from going on rampages, like the recent shooting in Kansas City?
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.